Skip to main content

Valbenazine Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Nov 10, 2021.


Commonly reported side effects of valbenazine include: drowsiness, fatigue, and sedated state. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to valbenazine: oral capsules

Side effects include:

Somnolence (including fatigue and sedation), anticholinergic effects (e.g., dry mouth, constipation, attention disturbance, blurred vision, urinary retention), balance disorders (including falls, gait disturbances, and dizziness), headache, akathisia/restlessness, vomiting, nausea, arthralgia.

For Healthcare Professionals

Applies to valbenazine: oral capsule


-The most common adverse reaction (5% or more and twice the rate of placebo) was somnolence.

-A total of 3% of patients discontinued treatment because of adverse reactions.[Ref]

Nervous system

Very common (10% or more): Somnolence/fatigue/sedation (10.9%)

Common (1% to 10%): Anticholinergic effects (dry mouth, constipation, attention disturbance, blurred vision, urinary retention), balance disorders/fall/gait disturbance/dizziness, headache, akathisia/restlessness, drooling, dyskinesia,

non-akathisia extrapyramidal symptoms[Ref]


Common (1% to 10%): Vomiting, nausea[Ref]


Common (1% to 10%): Increased alkaline phosphatase and bilirubin[Ref]


Common (1% to 10%): Increased blood glucose, increased weight, increased prolactin[Ref]


Common (1% to 10%): Arthralgia[Ref]


Common (1% to 10%): Anxiety, insomnia[Ref]


Common (1% to 10%): Respiratory infections[Ref]

Frequently asked questions

More about valbenazine

Patient resources

Other brands


Professional resources

Related treatment guides


1. "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc. (2017):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.